Comment on "Proton Pump Inhibitors Attenuate the Effectiveness of Nivolumab Monotherapy in Patients with Advanced Gastric Cancer: a Retrospective Study" [0.03%]
关于“质子泵抑制剂削弱纳武单抗单药治疗晚期胃癌患者疗效：一项回顾性研究”的评论
Francisco Cezar Aquino de Moraes
Francisco Cezar Aquino de Moraes
Efficacy and Safety of Different Treatment Regimens for Previously Untreated Patients with HER2-positive Advanced Gastric Cancer: A Meta-Analysis of Randomized Controlled Trials [0.03%]
不同新辅助及一线治疗方案用于HER2阳性胃癌患者疗效和安全性的 meta 分析：基于随机对照试验的系统综述
Yuqi He,Qi Kang,Shanshan Xu et al.
Yuqi He et al.
Objective: The development of treatments for advanced gastric cancer (AGC) has made significant advances over the past decade. Although clinical trials for novel drugs targeting HER2-positive AGC are ongoing, current clin...
Impact of Neoadjuvant Chemotherapy on Perioperative Tumor Marker Dynamics and Postoperative Recovery in Patients Undergoing Laparoscopic Radical Resection for Rectal Cancer [0.03%]
新辅助化疗对直肠癌腹腔镜根治术患者围手术期肿瘤标志物动态及术后康复的影响
Leibin Shen,Zhenglei Fei,Tao Peng et al.
Leibin Shen et al.
Background: The impact of neoadjuvant chemotherapy (NAC) on perioperative and functional outcomes for patients undergoing laparoscopic radical resection for rectal cancer remains incompletely understood. This study aimed ...
Neoadjuvant Immune Checkpoint Inhibition in MSI-H/dMMR Colorectal Cancer: A Systematic Review of Prospective Trials Evaluating Efficacy, Pathologic Response, and Surgical Outcomes [0.03%]
错配修复缺陷型结直肠癌新辅助免疫治疗：一项关于疗效、病理反应和手术结果的前瞻性研究系统评价
Wajahat Mirza,Mehak Ejaz Khan,Hania Iqbal et al.
Wajahat Mirza et al.
Background: Mismatch repair-deficient (dMMR) and microsatellite instability-high (MSI-H) colorectal cancers demonstrate exceptional responsiveness to immune checkpoint inhibitors; however, evidence for the efficacy of neo...
Sociodemographic Determinants Associated with the Receipt of Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Population-Based Study from the SEER Registry [0.03%]
基于SEER登记处III期结直肠癌辅助化疗影响因素的流行病学研究
Sameh Hany Emile,Nir Horesh,Zoe Garoufalia et al.
Sameh Hany Emile et al.
Background: Approximately 35% of patients do not receive adjuvant chemotherapy (AC) after surgery for stage III colorectal cancer (CRC). We aimed to investigate the association between receipt of AC and sociodemographic a...
Correction: Diagnostic Utility of Serum CEA and Ca 19.9 as Triage Tools for Predicting Metastatic Disease in Gallbladder Cancer: A Sub-analysis from a Prospective Observational Study [0.03%]
纠正：针对前瞻性观察性研究中胆囊癌远处转移预测的血清CEA和CA19.9诊断价值的亚组分析
Kumar Vineet,Mayank Tripathi,Chandan Kumar et al.
Kumar Vineet et al.
Published Erratum
Journal of gastrointestinal cancer. 2025 Dec 3;56(1):235. DOI:10.1007/s12029-025-01360-3 2025
Bioinformatics Analysis Reveals the Role of DLGAP4 in the Development and Progression of Hepatocellular Carcinoma [0.03%]
生物信息学分析揭示DLGAP4在肝细胞癌发生发展中的作用
Feng Yang,Shoufeng Chang,Ruxia Li et al.
Feng Yang et al.
Purpose: Although the DLGAP4 gene is well-established in neurological disorders, its function in hepatocellular carcinoma (HCC) remains unclear. This study aims to characterize DLGAP4 expression patterns, prognostic signi...
Clinical Efficacy and Safety of Gemcitabine-Cisplatin Combination in Metastatic Gallbladder Cancer: A Prospective Study from North India [0.03%]
吉西他滨-顺铂新组合方案治疗胆囊癌转移的临床疗效和安全性：一项来自印度北部的研究
Abhinav Dewan,Vineet Talwar,Varun Goel et al.
Abhinav Dewan et al.
Background: Gemcitabine-cisplatin doublet is a standard first-line regimen for metastatic gallbladder cancer (GBC), though prospective real-world data remains scarce. We evaluated the efficacy, safety, and prognostic fact...
Re-evaluating Gastric Ulcer Re-evaluation: Low Malignancy Yield and High Cost in a 19-Year Retrospective Cohort Study [0.03%]
胃溃疡复查的再评价：19年回顾性队列研究中的低癌变率和高成本
Thomas Matthews,Mark Vesey,Aditya Billur et al.
Thomas Matthews et al.
Background: Routine endoscopic re-evaluation of gastric ulcers (GUs) is widely recommended to exclude malignancy. However, in modern practice, particularly in low-to-intermediate gastric cancer prevalence settings, the di...